Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors

Leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) are quiescent, insensitive to BCR-ABL1 tyrosine kinase inhibitors (TKIs) and responsible for CML relapse. Therefore, eradicating quiescent CML LSCs is a major goal in CML therapy. Here, using a G(0) marker (G(0)M), we narrow down CML LSCs...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Yosuke, Takeda, Reina, Fukushima, Tsuyoshi, Mikami, Keiko, Tsuchiya, Shun, Tamura, Moe, Adachi, Keito, Umemoto, Terumasa, Asada, Shuhei, Watanabe, Naoki, Morishita, Soji, Imai, Misa, Nagata, Masayoshi, Araki, Marito, Takizawa, Hitoshi, Fukuyama, Tomofusa, Lamagna, Chrystelle, Masuda, Esteban S., Ito, Ryoji, Goyama, Susumu, Komatsu, Norio, Takaku, Tomoiku, Kitamura, Toshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755781/
https://www.ncbi.nlm.nih.gov/pubmed/35022428
http://dx.doi.org/10.1038/s41467-021-27928-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755781/
https://www.ncbi.nlm.nih.gov/pubmed/35022428
http://dx.doi.org/10.1038/s41467-021-27928-8

Ejemplares similares